MS Speaks

Multiple Sclerosis => TREATMENTS => Topic started by: agate on November 13, 2017, 05:33:39 pm

Title: (ECTRIMS) MS therapy GNbAC1 promotes myelin rejuvenation, study shows
Post by: agate on November 13, 2017, 05:33:39 pm

From Multiple Sclerosis News Today, October 30, 2017:

https://multiplesclerosisnewstoday.com/2017/10/30/msparis2017-trial-shows-gnbac1-promotes-rejuvenation-of-coating-that-protects-nerve-cells/?utm_source=Multiple+Sclerosis&utm_campaign=1f6e31c21f-RSS_US_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-1f6e31c21f-71286581 (https://multiplesclerosisnewstoday.com/2017/10/30/msparis2017-trial-shows-gnbac1-promotes-rejuvenation-of-coating-that-protects-nerve-cells/?utm_source=Multiple+Sclerosis&utm_campaign=1f6e31c21f-RSS_US_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-1f6e31c21f-71286581)

Title: Update on temelimab (GNbAC1)
Post by: agate on April 27, 2020, 08:52:50 pm

Trials of GNbAC1 (temelimab) have been delayed due to the COVID-19 outbreak. Some information about it:


https://www.mstrust.org.uk/a-z/temelimab


About the postponement, from  Yahoo Finance News (April 26, 2020):


https://finance.yahoo.com/news/geneuro-financial-information-business-first-053000714.html